<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04829422</url>
  </required_header>
  <id_info>
    <org_study_id>LASER-EAP</org_study_id>
    <nct_id>NCT04829422</nct_id>
  </id_info>
  <brief_title>Early Access Program of Lazertinib in Republic of Korea</brief_title>
  <official_title>Multi-center, Prospective, Early Access Program of Lazertinib in Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients With T790M Mutation-positive After 1st/2nd Generation EGFR TKIs Therapy to Assess the Safety and Efficacy of Real World Evidence.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <brief_summary>
    <textblock>
      This early access program will be conducted to provide access to Lazertinib for adult&#xD;
      patients with locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with T790M&#xD;
      mutation-positive after 1st/2nd generation EGFR TKIs Therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lazertinib is an oral, highly potent, mutant-selective and irreversible EGFR Tyrosine-kinase&#xD;
      inhibitors (TKIs) targets both the T790M mutation and activating EGFR mutations while sparing&#xD;
      wild type-EGFR.&#xD;
&#xD;
      This is a Multi-center, Prospective, Early Access Program of Lazertinib in locally advanced&#xD;
      or metastatic Non-small Cell Lung Cancer (NSCLC) patients with T790M mutation-positive after&#xD;
      1st/2nd generation EGFR TKIs therapy to assess the safety and efficacy of real world evidence&#xD;
      as second-line treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lazertinib 240 mg</intervention_name>
    <description>The initial dose of lazertinib 240 mg (3 tablets of 80 mg lazertinib) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib) under specific circumstances</description>
    <other_name>Leclaza 240 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged at least 19 years&#xD;
&#xD;
          -  Patients who have written consent for use of personal and medical information for the&#xD;
             study purpose&#xD;
&#xD;
          -  Patients who are prescribed and administered with approved indication for Lazerinib in&#xD;
             Korea and not been treated with Lazertinib previously.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with hypersensitivity to Lazertinib or its any ingredients&#xD;
&#xD;
          -  Patients who belong to contraindication listed on lazertinib label in Korea&#xD;
&#xD;
          -  Patients who are treated for an indication not approved for the use of Lazertinib&#xD;
&#xD;
          -  Women who are pregnant or may possibly become pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Sungjae Lee</last_name>
    <phone>+82-2-828-0366</phone>
    <email>sjlee@yuhan.co.kr</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lazertinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

